Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day: dFLC over 180 mg/L may no longer holds prognostic value in era of CyBorD/DaraCyBorD-based AL amyloidosis therapy and question utility of Mayo 2012 staging system in the era of highly effective chemo-immunotherapies.”
Title: Predictive Value of Free Light Chain Burden in Patients with AL Amyloidosis Treated with Bortezomib-Based Regimens
Authors: Brendan Saunders, Foteini Theodorakakou, Despina V Fotiou, Samuel Boullt, Benjamin Evans, Meletios Athanasios Dimopoulos, Efstathios Kastritis, Giada Bianchi.
You can read the Full Article on Blood Advances.
More posts featuring Robert Orlowski.
